Welcome to LookChem.com Sign In|Join Free
  • or
IBOGAMINE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

481-87-8

Post Buying Request

481-87-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

481-87-8 Usage

Uses

Ibogamine is used for treatment of movement-related disorders using noribogaine.

Check Digit Verification of cas no

The CAS Registry Mumber 481-87-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,8 and 1 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 481-87:
(5*4)+(4*8)+(3*1)+(2*8)+(1*7)=78
78 % 10 = 8
So 481-87-8 is a valid CAS Registry Number.
InChI:InChI=1/C19H24N2/c1-2-13-9-12-10-16-18-15(7-8-21(11-12)19(13)16)14-5-3-4-6-17(14)20-18/h3-6,12-13,16,19-20H,2,7-11H2,1H3/t12-,13+,16?,19?/m0/s1

481-87-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name ibogamine

1.2 Other means of identification

Product number -
Other names racem. Ibogamin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:481-87-8 SDS

481-87-8Downstream Products

481-87-8Relevant academic research and scientific papers

IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS

-

Page/Page column 67, (2022/02/05)

The present invention provides a compound having the structure: formula wherein X1 is H or alkyl; Y1 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -cycloalkyl, - aryl, heteroaryl, -alkyl-Y3 or -alkyl-C(O)Y4, and Y2 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -cycloalkyl, - aryl, heteroaryl, -alkyl-Yg or -alkyl-C(O)Y4, wherein each Y3 is, independently, -OH, -O(alkyl), -NH2, - NH(alkyl) or halogen, and each Y4 is, independently, -OH, -O(alkyl), -NH2, -NH(alkyl) or -N(alkyl)2; Z1 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -aryl, heteroaryl, -alkyl-Zg or -alkyl-C(O)Z4, and Z2 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -aryl, heteroaryl, -alkyl-Zg or -alkyl-C(O)Z4, wherein each Z3 is, independently, -OH, -O(alkyl), -NH2, - NH(alkyl) or halogen, and each Z4 is, independently, -OH, -O(alkyl), -NH2, -NH(alkyl) or -N(alkyl)2; R1, R2, R3 and R4 are each, independently, -H, -F, -Cl, -Br, -I, -NO2, -CN, -CF3, -CF2H, -OCF3, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -OH, -OAc, -O-(alkyl), -O-(alkenyl), - O-(alkynyl), -O-(aryl), -O-(heteroaryl), -SH, -S-(alkyl), S (alkenyl), -S-(alkynyl), -S-(aryl), -S-(heteroaryl), -NH2, -NH- (alkyl), -NH-(alkenyl), -NH-(alkynyl), -NH-(aryl), -NH- (heteroaryl), -C(0)R5, -S(O)R5, -SO2R5, -NHSO2R5, -0C(0)R5, SC(0)R5, -NHC(O)R6 or -NHC(S)R6, wherein each R5 is, independently, -(alkyl), -(aryl), (heteroaryl), -OH, -O(alkyl), -NH2, -NH(alkyl) or N(alkyl)2, and wherein each R6 is, independently, -(alkyl), -(aryl), -O- (alkyl), -S-(alkyl), -S-(aryl), -NH2, -NH(alkyl) or N(alkyl)2, wherein the compound is other than any of ibogaine, ibogamine, N- methyl-ibogaine, N-methyl-noribogaine, N-ethyl-noribogaine, N-methyl- ibogamine or 10-ethoxy-ibogamine, or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, substance use disorders, opioid use disorders, and opioid withdrawal symptoms.

Reductive Heck coupling: An efficient approach toward the iboga alkaloids. Synthesis of ibogamine, epiibogamine and iboga analogs

Jana, Goutam Kumar,Sinha, Surajit

, p. 1671 - 1674 (2012/04/11)

A mild and efficient synthetic route to the iboga scaffold by employing reductive-Heck type annulation is described. The utility of this process is demonstrated by the direct access to the ibogamine, epiibogamine and iboga-analogs. The cyclization precursors were readily obtained from 2-iodoaniline by heteroannulation reaction with suitable alkynes followed by iodination.

Catalyzed asymmetric Diels - Alder reactions of benzoquinone. Total synthesis of (-)-ibogamine

White, James D.,Choi, Younggi

, p. 4306 - 4327 (2007/10/03)

The Diels - Alder reaction of 1,4-benzoquinone with 1,3-dienes catalyzed by Mikami's [Ti{(S)-binol(2 -)}Cl2] complex (binol = [1,1′-binaphthalene]-2,2′-diol) gives cycloadducts in good yield and in high enantiomer excess. A model is proposed to

Catalyzed asymmetric Diels-Alder reaction of benzoquinone. Total synthesis of (-)-ibogamine

White, James D.,Choi, Younggi

, p. 2373 - 2376 (2007/10/03)

(equation presented) The Diels-Alder addition of diene 2 with benzoquinone catalyzed by (S)-BINOL-TiCl2 produced cycloadduct 5 in >65% yield and 87% ee. The cycloadduct was transformed into (-)-ibogamine in nine steps (10% overall yield from be

A novel approach to iboga alkaloids: Total synthesis of (±)-ibogamine and (±)-epi-ibogamine

Henry Jr., Kenneth J.,Grieco, Paul A.,DuBay, William J.

, p. 8289 - 8292 (2007/10/03)

A novel approach to the total synthesis of (±)-ibogamine and (±)-epi-ibogamine, featuring electrophilic substitution at C(2) of N'-CBZ-tryptamine by an allylic acetate, is described.

1,6-dihydro-3(2H)-pyridinones. X. 2-azabicyclooctane Ring Formation via Intramolecular Michael reaction: Total synthesis of (+/-)-Ibogamine and (+/-)-Epiibogamine

Imanishi, Takeshi,Yagi, Noriyuki,Hanaoka, Miyoji

, p. 4202 - 4211 (2007/10/02)

A new elaboration method for the 2-azabicyclooctane ring via an intramolecular Michael reaction has been developed and applied to the total synthesis of (+/-)-ibogamine (1) and (+/-)-epiibogamine (2).The unsaturated estert (9) derived from ethyl 1,

Alkaloid studies. 8. Isolation and characterization of alkaloids of Tabernaemontana heyneana Wall and antifertility properties of coronaridine.

Meyer,Coppola,Goldman

, p. 1199 - 1201 (2007/10/09)

In this study, the roots of Tabernaemontana heyneana Wall were examined and the isolation and identification of additional indole alkaloids and some pharmacological properties of coronaridine are described. Extraction of the roots yielded the alkaloids coronaridine, voacangine, ibogamine, 19-oxocoronaridine, and the pseudoindoxyl of voacangine. An acqueous ethanolic extract of the roots was found to prevent fertilization of adult female rats when administered orally. After the residue of this extract was treated chromatographic fractionation on silica gel yielded the alkaloid coronaridine. When administered to adult female rats, orally, coronaridine hydrochloride at levels of 5 mg/kg/day or above prevented pregnancy. Voacangine, assayed by the same procedure, did not prevent pregnancies. Data indicated that coronaridine was weakly estrogenic.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 481-87-8